Abstract
Purpose: :
To evaluate the safety and efficacy of intravitreal Avastin in the treatment of myopic choroidal neovascular membrane (mCNV).
Methods: :
18 eyes of 17 patients, receiving intravitreal Avastin for mCNV were retrospectively analyzed for changes in the best corrected visual acuity(BCVA),Fluorescein angiography(FFA),and optical coherence tomography(OCT).
Results: :
18 eyes of 17 patients were followed up for a mean period of 9.27(range 6-15) months. The Mean spherical equivalent refractive error of the 18 eyes was -14.75 D (range, -6 to -24 D).The mean ± standard deviation (SD) logarithm of the minimum angle of resolution (logMAR) BCVA at baseline was 0.28±0.20 (snellen equivalent,20/80). At the last follow up the mean logMAR BCVA improved to 0.42 (snellen equivalent,20/40;p<0.003).vision improved by a mean of 1.7 (range, 0-6) lines on the snellen visual acuity chart. The mean ± SD baseline central retinal thickness (CRT) of 288±60.36µm reduced to 209µm ± 46.91µm (p<0.0001).The mean number of injections per eye was 2.8 (range1-5). Leakage from the mCNV had resolved in 15 of the 18 eyes and was reduced in 3 eyes. No ocular or systemic adverse affects were noted.
Conclusions: :
Intravitreal Avastin is a safe and effective treatment option for mCNV, resulting in improved visual acuity and central retinal thickness. Larger prospective controlled trials with a longer follow up are needed to study the optimal treatment regime, safety and dosage.
Keywords: vascular endothelial growth factor • choroid: neovascularization • myopia